The FDA Grants Fast Track Designation to Novel GPRC5D/CD3 Bispecific Antibody LBL‑034 for Relapsed/Refractory Multiple Myeloma
The Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to LBL‑034, an investigational GPRC5D/CD3 bispecific T‑cell engager, for the treatment of patients with relapsed or refractory multiple myeloma. The designation is based on encouraging safety, efficacy, and durability signals